Suraksha Diagnostic Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported strong revenue growth for FY2026 with standalone revenue up 20.7% to ₹30,068 lakhs from ₹24,910 lakhs in FY2025. Consolidated revenue grew 23.2% to ₹31,041 lakhs. Standalone profit after tax increased marginally by 1.9% to ₹3,406 lakhs, while consolidated PAT rose 1.4% to ₹3,140 lakhs. The company declared a dividend of ₹0.50 per equity share (25%) for FY2025-26, compared to nil dividend in the previous year. Auditors MSKA & Associates issued an unmodified (clean) opinion on both standalone and consolidated results. A step-down subsidiary is involved in a dispute with the Government of Meghalaya, with ₹392.20 lakhs in investments and loans under assessment. The company also completed acquisition of Fetomat Wellness Private Limited in April 2025.
Revenue growth of over 20% is positive, but profit growth lagging at under 2% suggests margin pressure. The dividend resumption signals management confidence. The dispute in the step-down subsidiary involving government entities adds some risk visibility.